SEC Filing Summary: Synta Pharmaceuticals Corp.
Business Context and Reporting Period
This Form 8-K Current Report was filed by Synta Pharmaceuticals Corp. on April 6, 2015. The report discloses the closing of a previously announced public offering of common stock. Note: The request metadata references "Madrigal Pharmaceuticals, Inc.", but the filing text explicitly identifies the registrant as "Synta Pharmaceuticals Corp."
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial event reported is the issuance of 25,300,000 shares of common stock. This total includes 3,300,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares.
Material Changes
The material change reported is the increase in outstanding common stock resulting from the closing of the public offering on April 6, 2015. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or contingencies beyond the announcement of the stock offering. A press release dated April 6, 2015, is filed as Exhibit 99.1 and incorporated by reference, but its specific content regarding outlook is not detailed in this text.
Investor Verification Checklist
- Verify the exact offering price per share and total gross proceeds from the 25,300,000 shares issued.
- Review the full text of the press release (Exhibit 99.1) for details on the use of proceeds.
- Confirm the updated total number of outstanding shares post-offering.
- Clarify the discrepancy between the request metadata (Madrigal Pharmaceuticals) and the filing registrant (Synta Pharmaceuticals).